alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.
The biochemical and clinical efficacy of intravenous augmentation therapy in alpha(1)-antitrypsin deficiency is reviewed, adverse events experienced with this treatment are considered, and its cost effectiveness is discussed.
Stoller
J K
JK
Division of Medicine, Section of Respiratory Therapy, Cleveland Clinic Lerner School of Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. stollej@ccf.org
Aboussouan
L S
LS
D003362:Cost-Benefit Analysis; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007262:Infusions, Intravenous; D016896:Treatment Outcome; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage*; D019896:alpha 1-Antitrypsin Deficiency / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology
D000515:alpha 1-Antitrypsin